深度聚焦！极氪发布一季度财报：营收147.37亿元，同比增长71%，展现强劲增长势头

极氪发布一季度财报：营收147.37亿元，同比增长71%，展现强劲增长势头

北京讯 6月11日晚间，极氪（NYSE：ZK）发布了上市后的首份财报。财报显示，极氪2024年第一季度总收入为147.37亿元人民币，同比增长71.0%，较2023年第四季度下降9.9%。其中，汽车销售收入为81.714亿元（11.321亿美元），同比增长73.0%。

新车交付量强劲增长

在销量方面，极氪一季度共交付33,059台，同比增长117%。其中，极氪001交付29,468台，极氪X交付3,591台。

毛利率有所下滑

在盈利能力方面，极氪一季度整车毛利率为14%，同比提升3.9个百分点，不过较2023年15%的毛利率略有下滑。

海外市场拓展取得进展

截至5月底，极氪已进入荷兰、瑞典、泰国、阿联酋、沙特等20多个国家和地区。极氪001、极氪X率先在欧洲开启交付，右舵版极氪X将于三季度开启交付。预计到今年年底，极氪将进入欧洲8国豪华市场，以及东南亚、中东、拉美、大洋洲等全球50多个国家和地区。

总体而言，极氪一季度业绩表现亮眼，展现出强劲的增长势头。 极氪正在加速全球化布局，未来发展值得期待。

以下是一些可以参考的新闻来源：

• 极氪发布一季度财报：营收147.37亿元，同比增长71% [移除了无效网址]
• 极氪：一季度营收147.37亿元同比增长71% https://auto.gasgoo.com/news/202406/11I70395466C501.shtml
• 【图】营收147.37亿元极氪发布一季度财报 https://www.autohome.com.cn/news/202406/1297597.html

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.